By state-of-art computational protein design and deep learning-based prediction of protein-protein interaction combined with experimental methods, we create monoclonal antibodies (mAbs) against next-generation immunotherapeutic targets. These mAbs can be recreated into next-generation bispecific T-cell engagers, CAR-T receptor or antibody-drug conjugates.